Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
287.78
+5.33 (1.89%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 281.38 - 290.92
52 week 223.02 - 338.51
Open 282.09
Vol / Avg. 3.39M/2.03M
Mkt cap 64.25B
P/E 16.80
Div/yield     -
EPS 17.13
Shares 219.12M
Beta 0.90
Inst. own 89%
Oct 19, 2016
Q3 2016 Biogen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 28, 2016
Iraqi Islamic Bank for Investment and Development Annual Shareholders Meeting - 3:00AM EDT - Add to calendar
Jul 21, 2016
Q2 2016 Biogen Inc Earnings Release
Jul 21, 2016
Q2 2016 Biogen Inc Earnings Call - Webcast
Jun 9, 2016
Biogen Inc Annual Shareholders Meeting (Estimated)
Jun 8, 2016
Biogen Inc Annual Shareholders Meeting
May 3, 2016
Biogen Inc Conference Call on Hemophilia Spin off
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 36.22% 33.50%
Operating margin 50.46% 45.44%
EBITD margin - 52.17%
Return on average assets 19.93% 21.32%
Return on average equity 38.75% 35.15%
Employees 7,350 -
CDP Score - 96 C

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 68
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 59
Bio & Compensation  - Reuters
Michael D Ehlers M.D., Ph.D. Executive Vice President of Research and Development
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 62
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 53
Bio & Compensation  - Reuters
Adam M. Koppel M.D. Ph.D. Executive Vice President - Strategy and Business Development
Age: 46
Bio & Compensation  - Reuters
Paul McKenzie Ph.D. Executive Vice President - Pharmaceutical Operations & Technology
Bio & Compensation  - Reuters